收稿日期: 2024-04-10
网络出版日期: 2024-10-22
基金资助
国家自然科学基金项目(82274421);国家自然科学基金青年项目(82305246);青年岐黄学者培育项目(国中医药人教函（2022）256号);高水平大学专项(A1-2601-22-415-013)
Advancements in the investigation of cardiovascular risk associated with idiopathic inflammatory myopathy
Received date: 2024-04-10
Online published: 2024-10-22
陈向红 , 陈秀敏 , 周颖燕 , 李李 , 徐侦雄 . 特发性炎症性肌病心血管风险研究进展[J]. 实用医学杂志, 2024 , 40(19) : 2801 -2805 . DOI: 10.3969/j.issn.1006-5725.2024.19.023
The idiopathic inflammatory myopathies encompass a diverse array of autoimmune diseases， characterized by muscular inflammation and various extramuscular manifestations. These conditions have the potential to impact multiple organs， including the lungs， skin， joints， gastrointestinal tract， and heart. The defining features of these conditions are muscle weakness and myalgia. Although cardiac involvement is infrequent， its clinical manifestations are subtle and easily overlooked. Cardiac damage represents a significant contributor to mortality and morbidity in patients with idiopathic inflammatory myopathy. Early and accurate identification of cardiac involvement may facilitate improved patient outcomes. This article provides an overview of the potential etiology， clinical presentations， risk factors， biomarkers， and imaging studies for early diagnosis of cardiac involvement in idiopathic inflammatory myopathy. This review aims to enhance clinicians' understanding and diagnostic capabilities regarding cardiac involvement in idiopathic inflammatory myopathy while promoting early intervention strategies for lifelong management and improved prognosis.
| 1 | 中华医学会风湿病学分会. 多发性肌炎和皮肌炎诊断及治疗指南［J］. 中华风湿病学杂志， 2010，14（12）： 828-831. |
| 2 | 邱梦倩， 周蕾. 心肌标志物在评估特发性炎症性肌病心脏损伤中的价值［J］. 心血管病学进展， 2020，41（1）： 71-74. |
| 3 | FAIRLEY J L， WICKS I， PETERS S， et al. Defining cardiac involvement in idiopathic inflammatory myopathies： A systematic review［J］. Rheumatology （Oxford）， 2021，61（1）： 103-120. |
| 4 | SCHWARTZ T， DIEDERICHSEN L P， LUNDBERG I E， et al. Cardiac involvement in adult and juvenile idiopathic inflammatory myopathies［J］. RMD Open， 2016，2（2）： e000291. doi:10.1136/rmdopen-2016-000291 |
| 5 | JAYAKUMAR D， ZHANG R， WASSERMAN A， et al. Cardiac manifestations in idiopathic inflammatory myopathies： An overview［J］. Cardiol Rev， 2019，27（3）： 131-137. doi:10.1097/crd.0000000000000241 |
| 6 | 侯英超， 杨建勋. 特发性炎症性肌病相关心血管病变的研究进展［J］. 心血管康复医学杂志， 2023，32（6）： 632-635. |
| 7 | LIU Y， HSU J， LIU X， et al. Electrophysiological， structural， and functional disorders in patients with inflammatory cardiomyopathy secondary to inflammatory myopathy［J］. Ann Noninvasive Electrocardiol， 2022，27（4）： e12938. doi:10.1111/anec.12938 |
| 8 | XIONG A， HU Z， ZHOU S， et al. Cardiovascular events in adult polymyositis and dermatomyositis： a meta-analysis of observational studies［J］. Rheumatology， 2022，61（7）： 2728-2739. doi:10.1093/rheumatology/keab851 |
| 9 | LAZZERINI P E， CAPECCHI P L， EL-SHERIF N， et al. Emerging arrhythmic risk of autoimmune and inflammatory cardiac channelopathies［J］. J Am Heart Assoc， 2018，7（22）： e010595. doi:10.1161/jaha.118.010595 |
| 10 | NAARAAYAN A， MEREDITH A， NIMKAR A， et al. Arrhythmia prevalence among patients with polymyositis-dermatomyositis in the United States： An observational study［J］. Heart Rhythm， 2021，18（9）： 1516-1523. doi:10.1016/j.hrthm.2021.05.029 |
| 11 | ORESKA S， STORKANOVA H， PEKACOVA A， et al. Cardiovascular risk in myositis patients compared with the general population［J］. Rheumatology， （Oxford）， 2024，63（3）：715-724. |
| 12 | AMBROSI A， DZIKAITE V， PARK J， et al. Anti-Ro52 monoclonal antibodies specific for amino acid 200-239， but not other Ro52 epitopes， induce congenital heart block in a rat model［J］. Ann Rheum Dis， 2012，71（3）： 448-454. |
| 13 | ALBAYDA J， KHAN A， CASCIOLA-ROSEN L， et al. Inflammatory myopathy associated with anti-mitochondrial antibodies： A distinct phenotype with cardiac involvement［J］. Semin Arthritis Rheum， 2018，47（4）： 552-556. |
| 14 | HUANG R， ZHANG X， HAN Z， et al. Refractory ventricular tachycardia and heart failure due to anti-mitochondrial antibody-positive inflammatory myopathy［J］. BMC Cardiovasc Disord， 2023，23（1）： 57. doi:10.1186/s12872-023-03057-6 |
| 15 | LIU Y， FANG L， CHEN W， et al. Identification of characteristics of overt myocarditis in adult patients with idiopathic inflammatory myopathies［J］. Cardiovasc Diagn Ther， 2020，10（3）： 405-420. doi:10.21037/cdt.2020.03.04 |
| 16 | MONDAL S， BARMAN P， VIGNESH P. Cardiovascular abnormalities in juvenile dermatomyositis： A scoping review for the clinical rheumatologists［J］. Front Med， 2022，9：827539. doi:10.3389/fmed.2022.827539 |
| 17 | BETTERIDGE Z， TANSLEY S， SHADDICK G， et al. Frequency， mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients［J］. J Autoimmun， 2019，101： 48-55. doi:10.1016/j.jaut.2019.04.001 |
| 18 | ZAMORA E， SEDER-COLOMINA E， HOLGADO S， et al. Heart lung muscle anti-SAE syndrome： An atypical severe combination［J］. J Clin Med， 2018，8（1）：20. |
| 19 | QUINTERO-GONZáLEZ D C， NAVARRO-BELE?O K， LóPEZ-GUTIéRREZ L V， et al. Cardiac involvement in anti-MDA5 dermatomyositis： A case-based review［J］. Clin Rheumatol， 2023，42（3）： 949-958. doi:10.1007/s10067-022-06401-x |
| 20 | MATSUO T， SASAI T， NAKASHIMA R， et al. ECG changes through immunosuppressive therapy indicate cardiac abnormality in anti-MDA5 antibody-positive clinically amyopathic dermatomyositis［J］. Front Immunol， 2022，12：765140. doi:10.3389/fimmu.2021.765140 |
| 21 | ZHOU S， LAI J， WU C， et al. Myocardial involvement is not rare in anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis/clinically amyopathic dermatomyositis： A retrospective study［J］. Front Immunol， 2022，13：928861. doi:10.3389/fimmu.2022.928861 |
| 22 | 王琰. 特发性炎症性肌病相关心脏损害特点分析［D］. 郑州：郑州大学， 2021. |
| 23 | WALKER B R. Glucocorticoids and cardiovascular disease［J］. Eur J Endocrinol， 2007，157（5）： 545-559. doi:10.1530/eje-07-0455 |
| 24 | DROSOS G C， VEDDER D， HOUBEN E， et al. EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases， including systemic lupus erythematosus and antiphospholipid syndrome［J］. Ann Rheum Dis， 2022，81（6）： 768-779. |
| 25 | D'ANDREA E， DESAI R J， HE M， et al. Cardiovascular Risks of hydroxychloroquine vs methotrexate in patients with rheumatoid arthritis［J］. J Am Coll Cardiol， 2022，80（1）： 36-46. doi:10.1016/j.jacc.2022.04.039 |
| 26 | XIE W， HUANG Y， XIAO S， et al. Impact of Janus kinase inhibitors on risk of cardiovascular events in patients with rheumatoid arthritis： systematic review and meta-analysis of randomised controlled trials［J］. Ann Rheum Dis， 2019，78（8）： 1048-1054. |
| 27 | ATZENI F， POPA C D， NUCERA V， et al. Safety of JAK inhibitors： Focus on cardiovascular and thromboembolic events［J］. Expert Rev Clin Immunol， 2022，18（3）： 233-244. doi:10.1080/1744666x.2022.2039630 |
| 28 | BELLOSTA S， CORSINI A. Statin drug interactions and related adverse reactions： An update［J］. Expert Opin Drug Saf， 2018，17（1）： 25-37. doi:10.1080/14740338.2018.1394455 |
| 29 | B?L?NESCU A R， BOJINC? V C， BOJINC? M. Cardiovascular effects of methotrexate in immune-mediated inflammatory diseases［J］. Exp Ther Med， 2019，17（2）： 1024-1029. |
| 30 | LIU Y， FANG L， CHEN W， et al. Clinical characteristics， treatment， and outcomes in patients with idiopathic inflammatory myopathy concomitant with heart failure［J］. Int Heart J， 2020，61（5）： 1005-1013. doi:10.1536/ihj.19-568 |
| 31 | 彭方琴. 肿瘤标志物CA125与特发性炎症性肌病心血管危险因素及心血管疾病的研究［D］. 泸州：西南医科大学， 2018. |
| 32 | DIEDERICHSEN L P， DIEDERICHSEN A C， SIMONSEN J A， et al. Traditional cardiovascular risk factors and coronary artery calcification in adults with polymyositis and dermatomyositis： A Danish multicenter study［J］. Arthritis Care Res （Hoboken）， 2015，67（6）： 848-854. |
| 33 | WELSH P， PREISS D， HAYWARD C， et al. Cardiac troponin T and troponin I in the general population［J］. Circulation， 2019，139（24）： 2754-2764. doi:10.1161/circulationaha.118.038529 |
| 34 | BARTH Z， NOMELAND W B， SCHWARTZ T， et al. In juvenile dermatomyositis， heart rate variability is reduced， and associated with both cardiac dysfunction and markers of inflammation： a cross-sectional study median 13.5 years after symptom onset［J］. Rheumatology （Oxford）， 2016，55（3）： 535-543. |
| 35 | QIU M， SUN X， QI X， et al. The diagnostic value of GDF-15 for myocardial involvement in idiopathic inflammatory myopathy［J］. Rheumatology， 2021，60（6）： 2826-2833. doi:10.1093/rheumatology/keaa721 |
| 36 | ZHANG Y， SHAN L， LI D， et al. Identification of key biomarkers associated with immune cells infiltration for myocardial injury in dermatomyositis by integrated bioinformatics analysis［J］. Arthritis Res Ther， 2023，25（1）：69. doi:10.1186/s13075-023-03052-4 |
| 37 | 李楠， 康志雷. 3.0T CMR定量技术诊断急性病毒性心肌炎效能及评估短期预后的价值［J］. 实用医学杂志， 2023，39（9）： 1169-1173. |
| 38 | OLDROYD A G S， LILLEKER J B， AMIN T， et al. British Society for Rheumatology guideline on management of paediatric， adolescent and adult patients with idiopathic inflammatory myopathy［J］. Rheumatology， 2022，61（5）： 1760-1768. doi:10.1093/rheumatology/keac115 |
| 39 | PUJADES-RODRIGUEZ M， MORGAN A W， CUBBON R M， et al. Dose-dependent oral glucocorticoid cardiovascular risks in people with immune-mediated inflammatory diseases： A population-based cohort study［J］. PLoS Med， 2020，17（12）： e1003432. |
| 40 | B?L?NESCU A R， BOJINC? V C， BOJINC? M， et al. Cardiovascular effects of methotrexate in immune-mediated inflammatory diseases［J］. Exp Ther Med， 2019，17（2）： 1024-1029. |
| 41 | van LEUVEN S I， KASTELEIN J J， ALLISON A C， et al. Mycophenolate mofetil （MMF）： Firing at the atherosclerotic plaque from different angles？［J］. Cardiovasc Res， 2006，69（2）： 341-347. doi:10.1016/j.cardiores.2005.09.018 |
| 42 | ALLANORE Y， VIGNAUX O， ARNAUD L， et al. Effects of corticosteroids and immunosuppressors on idiopathic inflammatory myopathy related myocarditis evaluated by magnetic resonance imaging［J］. Ann Rheum Dis， 2006，65（2）： 249-252. |
| 43 | KOTANI T， MAKINO S， TAKEUCHI T， et al. Early intervention with corticosteroids and cyclosporin A and 2-hour postdose blood concentration monitoring improves the prognosis of acute/subacute interstitial pneumonia in dermatomyositis［J］. J Rheumatol， 2008，35（2）： 254-259. |
| 44 | BECKETT M， TAN J， BONNARDEAUX E， et al. Tofacitinib therapy in refractory inflammatory myositis： A retrospective cohort study of 41 patients［J］. Rheumatology （Oxford）， 2024，63（5）：1432-1436. |
| 45 | LANDON-CARDINAL O， GUILLAUME-JUGNOT P， TOQUET S， et al. JAK inhibitors for the treatment of adult dermatomyositis： A pilot study［J］. J Am Acad Dermatol， 2023，88（4）： 924-926. doi:10.1016/j.jaad.2022.10.055 |
| 46 | GRAZZINI S， RIZZO C， CONTICINI E， et al. The role of bDMARDs in idiopathic inflammatory myopathies： A systematic literature review［J］. Autoimmun Rev， 2023，22（2）： 103264. doi:10.1016/j.autrev.2022.103264 |
| 47 | MCHUGH J. Cancer and cardiovascular risk with JAK inhibition［J］. Nat Rev Rheumatol， 2023，19（2）： 64. doi:10.1038/s41584-022-00901-5 |
| 48 | MATTAY S S， ZAMANI M， SATURNO D， et al. Risk of major adverse cardiovascular events in immune-mediated inflammatory disorders on biologics and small molecules： Network meta-analysis［J］. Clin Gastroenterol Hepatol，2024，22（5）：961-970.e12. doi:10.1016/j.cgh.2023.09.033 |
| 49 | OLDROYD A， LILLEKER J B， AMIN T， et al. British society for Rheumatology guideline on management of paediatric， adolescent and adult patients with idiopathic inflammatory myopathy［J］. Rheumatology （Oxford）， 2022，61（5）： 1760-1768. doi:10.1093/rheumatology/keac115 |
| 50 | 骆骏骞， 邓志文， 黎土娣， 等. 心力衰竭的治疗进展［J］. 实用医学杂志， 2022，38（10）： 1181-1186. doi:10.3969/j.issn.1006-5725.2022.10.002 |
/
| 〈 |
|
〉 |